Skip to main content
NewslettersWatchlist

Verastem Inc(VSTM-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low12.00
Day High13.16
Open:13.16
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Barchart
Markets Today: Stocks Firm on Hopes for Additional Chinese Stimulus
Barchart
Stock Index Futures Move Higher as Investors Weigh Interest Rate Outlook, China Stimulus Hopes Boost Sentiment
Barchart
Markets Jump to 14-Month highs
PR Newswire
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
Business Wire
Verastem Oncology to Participate in Upcoming Investor Conferences
Business Wire
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting
Business Wire
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer
Business Wire
Verastem Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress
Business Wire
Verastem Oncology Outlines Key 2023 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib as a Backbone of Therapy for RAS Pathway-Driven Cancers
Business Wire
Verastem Oncology Announces Up to $60 Million Private Placement Offering of Series B Convertible Preferred Stock
Business Wire
Verastem Oncology Announces Positive Data and Regulatory Update from Planned Interim Analysis of Registration-Directed Phase 2 RAMP-201 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
Verastem Oncology Appoints Rob Gagnon to Board of Directors
Business Wire
Verastem Oncology Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
Business Wire
Verastem Oncology Appoints Anil Kapur to Board of Directors
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates
Business Wire
Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer
Business Wire
Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer
Business Wire
Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
Business Wire
Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors
Business Wire
Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory Board
Business Wire
Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers
Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
Verastem Oncology to Participate in Upcoming Investor Conferences
Business Wire
Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer

Profile

Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.